^
    17h
    Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) (clinicaltrials.gov)
    P2, N=408, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • paclitaxel • docetaxel • Lenvima (lenvatinib) • capecitabine
    18h
    Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer (clinicaltrials.gov)
    P2, N=29, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Lenvima (lenvatinib) • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1d
    KEYNOTE-B61: Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) (clinicaltrials.gov)
    P2, N=160, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    3d
    Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Universität des Saarlandes | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Jan 2027 | Trial primary completion date: Sep 2025 --> Jan 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    4d
    A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Fudan University
    New P2 trial
    |
    Lenvima (lenvatinib) • Enweida (envafolimab)
    4d
    Machine Learning-Based Survival Analysis for Patients Receiving Lenvatinib for Unresectable Hepatocellular Carcinoma. (PubMed, J Hepatocell Carcinoma)
    These models have the potential to guide clinicians' treatment decisions and provide prognostic evaluations. Future prospective studies with larger cohorts, as well as integration of imaging biomarkers are warranted to optimize these predictive models.
    Journal
    |
    AFP (Alpha-fetoprotein)
    |
    Lenvima (lenvatinib)
    4d
    Long-Term Disease Control With Lenvatinib in Metastatic Malignant Struma Ovarii: A Case Report. (PubMed, Cureus)
    Subsequently, multiple hepatic metastases and pelvic dissemination developed, and conventional chemotherapy including bevacizumab was ineffective...Switching to sorafenib led to further progression, but reintroduction of LVB reduced Tg levels...The patient has survived seven years since recurrence, including six years on LVB. The tumor behaved similarly to poorly differentiated thyroid carcinoma, with Tg levels reflecting disease activity and LVB demonstrating the potential for long-term tumor control.
    Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • TG (Thyroglobulin)
    |
    NRAS mutation
    |
    Avastin (bevacizumab) • sorafenib • Lenvima (lenvatinib)
    6d
    Analysis of different prognoses in two hepatocellular carcinoma patients with pathological complete response after conversion therapy: a case report. (PubMed, J Med Case Rep)
    Although conversion therapy can significantly downstage advanced hepatocellular carcinoma and allow curative-intent resection, the variability in long-term outcomes highlights the critical importance of preoperative tumor characteristics and treatment response assessment. Optimizing patient selection and enhancing postoperative surveillance and intervention strategies may improve long-term outcomes for these patients.
    Journal
    |
    AFP (Alpha-fetoprotein)
    |
    AFP elevation
    |
    Lenvima (lenvatinib)
    7d
    Hepatic stellate cells shape the ECM-disorganized and immunosuppressive microenvironment via CCL11/CCR3 axis in lenvatinib-treated hepatocellular carcinoma. (PubMed, Cell Signal)
    In conclusion, CCL11 over-production drives HSC activation, creating an ECM-disorganized and immunosuppressive TME via the CCL11/CCR3 axis in LEN-treated HCC. Combination therapy with CCR3 inhibitor and LEN might represent a novel therapeutic strategy.
    Journal
    |
    S100A9 (S100 Calcium Binding Protein A9) • CCL11 (C-C Motif Chemokine Ligand 11) • COL3A1 (Collagen Type III Alpha 1 Chain) • MRC1 (Mannose Receptor C-Type 1) • CCR3 (C-C Motif Chemokine Receptor 3)
    |
    Lenvima (lenvatinib)
    8d
    DysUFMylation of SREBP1 Promotes the Progression of Hepatocellular Carcinoma by Reprogramming Lipid Metabolism. (PubMed, J Clin Transl Hepatol)
    UFMylation is a critical posttranslational modification that destabilizes SREBP1, and its dysregulation contributes to HCC progression. Targeting the UFMylation-SREBP1 axis, particularly through Fatostatin and Lenvatinib combination therapy, represents a novel therapeutic strategy for HCC.
    Journal
    |
    DDRGK1 (DDRGK Domain Containing 1)
    |
    Lenvima (lenvatinib)
    8d
    C-reactive protein flare: a promising prognostic predictor for patients with hepatocellular carcinoma treated with TACE combined with lenvatinib and immune checkpoint inhibitors. (PubMed, Front Immunol)
    Moreover, CRP responder and CRP flare-responder status were independent risk factors for OS (p < 0.001) and PFS (p < 0.001). CRP kinetics may have predictive value for prognosis in HCC patients undergoing TACE-LEN-ICIs.
    Retrospective data • Journal • Checkpoint inhibition
    |
    CRP (C-reactive protein)
    |
    Lenvima (lenvatinib)
    10d
    Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) (clinicaltrials.gov)
    P3, N=863, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jan 2027 --> Jun 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • paclitaxel • 5-fluorouracil • Lenvima (lenvatinib) • oxaliplatin • levoleucovorin calcium